Canada Approves NIOX MINO for Asthma Monitoring

Canada Approves NIOX MINO for Asthma Monitoring

SOLNA, Sweden - 3 September 2009 - Aerocrine AB today announced that Health
Canada's Therapeutic Products Directorate has approved Aerocrine's NIOX MINO®
technology for use in treating asthma. Canada's National Health Service may now
begin using the NIOX MINO, a medical device that provides a measure of the
degree of inflammation in the airways in a single breath.

“This is a significant milestone for Canadians living with asthma. Measuring and
controlling airway inflammation may contribute to improved diagnosis, treatment
and disease control,” says Chip Neff, President of Aerocrine Inc.

Asthma is a chronic condition characterized by an inflammation present in the
airways of the lungs. The more inflamed the airway, the more sensitive the
airway becomes, which leads to symptoms such as breathing difficulty. While the
inflammation is the underlying cause of asthma symptoms, it has not been
possible to measure in routine clinical practice. Instead, diagnosis and
treatment are typically based on the patient's symptoms and lung function. 

The founders of Aerocrine made the original discovery that nitric oxide in
exhaled breath is elevated in patients with asthma and the company has since
pioneered the development of the method to monitor airway inflammation by
measuring exhaled nitric oxide (eNO). To date, more than 2.5 million patient
tests have been performed across the world using Aerocrine's systems.

According to the Asthma Society of Canada, asthma afflicts some three million
Canadians including twelve percent of Canadian children. The prevalence of
asthma has increased over the last twenty years and it is the leading cause of
absenteeism from school and the third leading cause of work loss. Asthma is also
responsible for ten deaths per week, most of which could be prevented. 
Economically, over twelve billion dollars a year is spent on asthma in Canada. 

“Aerocrine's method to help better control asthma continues to gain acceptance
across the world through regulatory approvals, inclusions in clinical guidelines
and health insurance systems”, says Paul de Potocki, CEO of Aerocrine AB. “We
are excited about this possibility to offer our company's technology also to
people living with asthma in Canada”.

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 80
Chip Neff, President Aerocrine Inc, telephone: +1 919 696 4267

About Aerocrine
Aerocrine AB is a medical technology company focused on the improved management
and care of patients with inflammatory airway diseases. The pioneer and leader
in the technology to monitor and manage airway inflammation, Aerocrine markets
NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable
measurement of airway inflammation and may thus play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm
Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act. The information was submitted for publication at
08:00 am on September the 3rd 2009.